AIM - AIM Immunotech starts dosing in early-stage intranasal ampligen study

AIM ImmunoTech (AIM) has dosed the first healthy subjects in its Phase 1 clinical study on the safety of Ampligen as a potential intranasal therapy.AIM’s goal is to develop Ampligen as a potential intranasal prophylaxis or early-stage treatment for COVID-19 and other respiratory viral diseases.The trial, which is expected to enroll 40 healthy subjects, is designed to assess the safety, tolerability and biological activity of repeated administration of Ampligen intranasally."Prior results of in vitro modelling were promising, and we are highly encouraged by the potential of an intranasal prophylactic approach using Ampligen to prevent infection and spread of COVID-19," Thomas Equels said.

For further details see:

AIM Immunotech starts dosing in early-stage intranasal ampligen study